Rosen Law Firm Investigates ADMA Biologics for Misleading Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: PRnewswire
- Securities Claims Investigation: Rosen Law Firm has launched an investigation into ADMA Biologics due to allegations of issuing materially misleading business information, which could severely impact the company's reputation and stock price if proven true.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics' shares fell by 16.6% after short seller Culper Research alleged that the company engaged in channel stuffing to inflate revenue, indicating a significant loss of market confidence in the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no upfront costs for participants, thereby reducing legal risks for investors and encouraging more affected parties to join the lawsuit.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice to ADMA Biologics Shareholders Regarding Class Action
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of ADMA Biologics (NASDAQ:ADMA), encouraging those who purchased shares during the class period from August 9, 2024, to March 25, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations Overview: The complaint alleges that ADMA Biologics made materially false and misleading statements during the class period, including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls, which misrepresented the company's business and prospects.
- Participation Requirements: Shareholders must register by August 10, 2026, to participate in the class action, and upon registration, they will receive updates throughout the case lifecycle, with no cost or obligation to participate.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, ensuring companies adhere to responsible business practices.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Stock Price Plunge: ADMA Biologics' stock plummeted 16.6% on March 24, 2026, from $13.59 to $11.33 per share due to allegations of channel stuffing by Culper Research, resulting in significant investor losses.
- Lawsuit Details: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP against ADMA and its executives for violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors having until August 10, 2026, to apply to lead the case.
- Financial Manipulation Allegations: The report from Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates, which allowed the company to falsely report a 20% revenue growth instead of a 3% decline in 2025.
- Subsequent Impact: Following the negative news, ADMA's stock further declined to $8.29 per share by March 29, 2026, reflecting a 13.9% drop, indicating serious market concerns regarding the company's financial transparency.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: Purchasers of ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, which could negatively impact the company's reputation and stock price.
- Allegation Details: The lawsuit claims that ADMA Biologics and its executives failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially leading to a decline in investor confidence and affecting the company's future financing capabilities.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following a report from Culper Research on March 24, 2026, and dropped another 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its strong capabilities in handling similar cases, which may significantly influence the legal outcomes for ADMA Biologics.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing practices, which resulted in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success records, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, covering the period from August 9, 2024, to March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenues, and lacked adequate internal controls, resulting in misleading positive statements about the company's business prospects.
- Stock Price Impact: Following a report from Culper Research on March 24, 2026, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations and contingency fee arrangements for legal representation.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ADMA Biologics, seeking damages for investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The complaint alleges that ADMA engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about the company's business and prospects, which could erode investor confidence.
- Investor Participation: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, suggesting that the case may attract substantial investor involvement, thereby increasing the legal pressure on the company.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which could have profound implications for ADMA's future operations.
See More
Notice to ADMA Biologics Shareholders Regarding Class Action
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of ADMA Biologics (NASDAQ:ADMA), encouraging those who purchased shares during the class period from August 9, 2024, to March 25, 2026, to contact the firm regarding potential lead plaintiff appointment.
- Allegations Overview: The complaint alleges that ADMA Biologics made materially false and misleading statements during the class period, including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls, which misrepresented the company's business and prospects.
- Participation Requirements: Shareholders must register by August 10, 2026, to participate in the class action, and upon registration, they will receive updates throughout the case lifecycle, with no cost or obligation to participate.
- Law Firm Credentials: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to deceit and illegal business practices, ensuring companies adhere to responsible business practices.
See More
ADMA Biologics Faces Securities Fraud Class Action Lawsuit
- Stock Price Plunge: ADMA Biologics' stock plummeted 16.6% on March 24, 2026, from $13.59 to $11.33 per share due to allegations of channel stuffing by Culper Research, resulting in significant investor losses.
- Lawsuit Details: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP against ADMA and its executives for violating Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors having until August 10, 2026, to apply to lead the case.
- Financial Manipulation Allegations: The report from Culper Research revealed that ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates, which allowed the company to falsely report a 20% revenue growth instead of a 3% decline in 2025.
- Subsequent Impact: Following the negative news, ADMA's stock further declined to $8.29 per share by March 29, 2026, reflecting a 13.9% drop, indicating serious market concerns regarding the company's financial transparency.
See More
ADMA Biologics Class Action Lawsuit Notice
- Class Action Initiation: Purchasers of ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to apply as lead plaintiff in a class action lawsuit alleging violations of the Securities Exchange Act of 1934, which could negatively impact the company's reputation and stock price.
- Allegation Details: The lawsuit claims that ADMA Biologics and its executives failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially leading to a decline in investor confidence and affecting the company's future financing capabilities.
- Stock Price Volatility: According to the complaint, ADMA Biologics' stock price fell over 16% following a report from Culper Research on March 24, 2026, and dropped another 13% after the company's response, indicating market concerns regarding the company's financial transparency.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, recovering over $916 million for investors in 2025, demonstrating its strong capabilities in handling similar cases, which may significantly influence the legal outcomes for ADMA Biologics.
See More
Reminder for ADMA Biologics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing practices, which resulted in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its successful track record in this field.
- Investor Selection Advice: Investors are advised to carefully choose law firms with proven success records, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Securities Fraud Class Action Filed Against ADMA Biologics
- Lawsuit Background: A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) for securities fraud, covering the period from August 9, 2024, to March 25, 2026, alleging significant misstatements and omissions in financial reporting that undermine investor confidence.
- Key Allegations: The lawsuit claims that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenues, and lacked adequate internal controls, resulting in misleading positive statements about the company's business prospects.
- Stock Price Impact: Following a report from Culper Research on March 24, 2026, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, reflecting market concerns regarding the company's financial health.
- Investor Action: Affected investors must file for lead plaintiff status by August 10, 2026, to represent other investors in the lawsuit, with KTMC offering free case evaluations and contingency fee arrangements for legal representation.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ADMA Biologics, seeking damages for investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks that could impact the company's stock performance.
- Allegations Overview: The complaint alleges that ADMA engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in materially false and misleading statements about the company's business and prospects, which could erode investor confidence.
- Investor Participation: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, suggesting that the case may attract substantial investor involvement, thereby increasing the legal pressure on the company.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which could have profound implications for ADMA's future operations.
See More
